Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 25Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Colorectal Neoplasms 5Pancreatic Neoplasms 4Mesothelioma, Malignant 3Melanoma 3Colonic Neoplasms 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-squamous Non-small Cell Lung Cancer 2Neoplasms by Site 2Mesothelioma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Adenocarcinoma of Lung 2Vaccinia 1Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Pemetrexed × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡